Literature DB >> 18381428

Lkb1 deficiency causes prostate neoplasia in the mouse.

Helen B Pearson1, Afshan McCarthy, Christopher M P Collins, Alan Ashworth, Alan R Clarke.   

Abstract

Mutation of LKB1 is the key molecular event underlying Peutz-Jeghers syndrome, a dominantly inherited condition characterized by a predisposition to a range of malignancies, including those of the reproductive system. We report here the use of a Cre-LoxP strategy to directly address the role of Lkb1 in prostate neoplasia. Recombination of a LoxP-flanked Lkb1 allele within all four murine prostate lobes was mediated by spontaneous activation of a p450 CYP1A1-driven Cre recombinase transgene (termed AhCre). Homozygous mutation of Lkb1 in males expressing AhCre reduced longevity, with 100% manifesting atypical hyperplasia and 83% developing prostate intraepithelial neoplasia (PIN) of the anterior prostate within 2 to 4 months. We also observed focal hyperplasia of the dorsolateral and ventral lobes (61% and 56% incidence, respectively), bulbourethral gland cysts associated with atypical hyperplasia (100% incidence), hyperplasia of the urethra (39% incidence), and seminal vesicle squamous metaplasia (11% incidence). PIN foci overexpressed nuclear beta-catenin, p-Gsk3 beta, and downstream Wnt targets. Immunohistochemical analysis of foci also showed a reduction in Pten activation and up-regulation of both p-PDK1 (an AMPK kinase) and phosphorylated Akt. Our data are therefore consistent with deregulation of Wnt and phosphoinositide 3-kinase/Akt signaling cascades after loss of Lkb1 function. For the first time, this model establishes a link between the tumor suppressor Lkb1 and prostate neoplasia, highlighting a tumor suppressive role within the mouse and raising the possibility of a similar association in the human.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18381428     DOI: 10.1158/0008-5472.CAN-07-5169

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

1.  Liver kinase B1 (LKB1) in the pathogenesis of UVB-induced murine basal cell carcinoma.

Authors:  Yevgeniya A Byekova; Jennifer L Herrmann; Jianmin Xu; Craig A Elmets; Mohammad Athar
Journal:  Arch Biochem Biophys       Date:  2011-01-25       Impact factor: 4.013

Review 2.  The LKB1 complex-AMPK pathway: the tree that hides the forest.

Authors:  Michaël Sebbagh; Sylviane Olschwang; Marie-Josée Santoni; Jean-Paul Borg
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

3.  The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts.

Authors:  Joanna Zabkiewicz; Lorna Pearn; Robert K Hills; Rhys G Morgan; Alex Tonks; Alan K Burnett; Richard L Darley
Journal:  Haematologica       Date:  2013-12-13       Impact factor: 9.941

4.  Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38.

Authors:  Valentina Grossi; Giuseppe Lucarelli; Giovanna Forte; Alessia Peserico; Antonio Matrone; Aldo Germani; Monica Rutigliano; Alessandro Stella; Rosanna Bagnulo; Daria Loconte; Vanessa Galleggiante; Francesca Sanguedolce; Simona Cagiano; Pantaleo Bufo; Senia Trabucco; Eugenio Maiorano; Pasquale Ditonno; Michele Battaglia; Nicoletta Resta; Cristiano Simone
Journal:  Autophagy       Date:  2015-11-02       Impact factor: 16.016

Review 5.  Metabolic alterations and targeted therapies in prostate cancer.

Authors:  Richard Flavin; Giorgia Zadra; Massimo Loda
Journal:  J Pathol       Date:  2010-11-16       Impact factor: 7.996

6.  Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy.

Authors:  Cristina M Contreras; Esra A Akbay; Teresa D Gallardo; J Marshall Haynie; Sreenath Sharma; Osamu Tagao; Nabeel Bardeesy; Masaya Takahashi; Jeff Settleman; Kwok-Kin Wong; Diego H Castrillon
Journal:  Dis Model Mech       Date:  2010-02-08       Impact factor: 5.758

Review 7.  New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK.

Authors:  Giorgia Zadra; Carmen Priolo; Akash Patnaik; Massimo Loda
Journal:  Clin Cancer Res       Date:  2010-04-27       Impact factor: 12.531

8.  The LKB1-AMPK pathway: metabolism and growth control in tumour suppression.

Authors:  David B Shackelford; Reuben J Shaw
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

9.  Specific deletion of LKB1/Stk11 in the Müllerian duct mesenchyme drives hyperplasia of the periurethral stroma and tumorigenesis in male mice.

Authors:  Jitu W George; Amanda L Patterson; Pradeep S Tanwar; André Kajdacsy-Balla; Gail S Prins; Jose M Teixeira
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-13       Impact factor: 11.205

10.  PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.

Authors:  Jorge Blando; Melisa Portis; Fernando Benavides; Angela Alexander; Gordon Mills; Bhuvanesh Dave; Claudio J Conti; Jeri Kim; Cheryl Lyn Walker
Journal:  Am J Pathol       Date:  2009-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.